Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
44 studies found for:    Open Studies | "Helicobacter Infections"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Helicobacter Infections"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Comparison of 7-Day and 14-Day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication
Condition: Helicobacter Infection
Interventions: Drug: pantoprazole;   Drug: bismuth;   Drug: metronidazole;   Drug: tetracycline
2 Recruiting The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection
Condition: Helicobacter Infection
Interventions: Drug: 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole);   Procedure: 7 day tailored therapy based on antimicrobial susceptibility testing;   Drug: PPI based triple therapy [Esomeprazole, amoxicillin, clarithromycin];   Drug: bismuth quadruple therapy [Esomeprazole, Tri potassium dicitrate bismuthate, Metronidazole, Tetracycline];   Drug: moxifloxacin triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]
3 Unknown  Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection
Condition: Helicobacter Infection
Interventions: Drug: Standard Triple Therapy;   Drug: Sequential Therapy
4 Recruiting The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection
Condition: Helicobacter Infection
Interventions: Procedure: H. pylori culture and antimicrobial susceptibility testing;   Drug: 14 days empirical bismuth quadruple therapy (Proton pump inhibitor);   Drug: Metronidazole;   Drug: Tetracycline;   Drug: tripotassium dicitrate bismuthate;   Drug: 7 days tailored therapy Proton Pump Inhibitor;   Drug: Moxifloxacin;   Drug: Amoxicillin
5 Not yet recruiting Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy
Condition: Helicobacter Infections
Interventions: Procedure: Gastroscopy;   Device: EndoFaster test;   Other: Clo test;   Other: Faecal Helicobacter pylori antigen
6 Recruiting Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori
Condition: Helicobacter Infections
Interventions: Drug: Noltec tab. 10mg;   Drug: Chongkundang Amoxicillin Cap. 500mg;   Drug: Cravit Tab. 500mg
7 Unknown  Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection
Conditions: Helicobacter Infections;   Gastritis;   Gastric Ulcer;   Duodenal Ulcer
Intervention: Drug: rabeprazole, amoxicillin, clarithromycin, metronidazole
8 Unknown  Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori
Conditions: Helicobacter Infections;   Gastritis;   Gastric Ulcer;   Duodenal Ulcer
Intervention: Drug: Lansoprazole, clarithromycin, amoxicillin
9 Unknown  Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
Conditions: Parkinson's Disease;   Helicobacter Infections;   Motor Fluctuations
Interventions: Drug: clartihromycin, amoxicillin, and omeprazole;   Drug: placebo
10 Unknown  Immediate Detection of Helicobacter Infection With a New Electrochemical System.
Condition: H. Pylori Infection
Interventions: Device: Electrochemical H. pylori detection method;   Device: IHC;   Device: C13-urea breath test;   Device: HUT
11 Unknown  Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection
Condition: Helicobacter Pylori Infection
Interventions: Drug: 7-day quadruple therapy;   Drug: 10-day sequential therapy;   Drug: 7-day standard triple therapy
12 Recruiting Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection
Condition: Helicobacter Pylori Infection
Interventions: Drug: Reverse hybrid therapy;   Drug: Standard triple therapy
13 Recruiting Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy
Condition: Helicobacter Pylori Infection
Interventions: Drug: high dose dual therapy;   Drug: concomitant therapy
14 Recruiting Volatile Markers in Digestive Cancer
Conditions: Colorectal Cancer;   Colorectal Adenoma;   Gastric Cancer;   Peptic Ulcer Disease;   Atrophic Gastritis;   Intestinal Metaplasia;   H.Pylori Infection;   Normal Control;   Average-risk General Population
Interventions: Procedure: Breath sampling for volatile marker detection;   Procedure: Upper endoscopy with biopsies;   Procedure: Colonoscopy with biopsies or lesion removal when required;   Procedure: Plasma/serum sampling;   Procedure: Faecal sample acquisition;   Procedure: Histological evaluation of the surgery material
15 Recruiting Community-based Helicobacter Pylori Eradication
Condition: Helicobacter Pylori Infection
Intervention: Drug: Helicobacter pylori eradication
16 Recruiting Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality
Conditions: Helicobacter Pylori Infections;   Atrophic Gastritis;   Gastric Cancer
Intervention: Drug: Triple therapy
17 Unknown  Effects of Dietary Heme/Non-heme Iron and Helicobacter Pylori (Hp) Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes
Conditions: Pregnancy;   Helicobacter Pylori Infection;   Iron-Deficiency Anemia
Intervention:
18 Unknown  Efficacy and Safety of InSan Bamboo Salt on Improvement of Helicobacter Pylori Infection
Condition: Helicobacter Pylori Infection
Interventions: Dietary Supplement: InSan Bamboo Salt;   Dietary Supplement: Placebo
19 Unknown  The Revolutions of Helicobacter Pylori Infection, Bacterial Density, and Histological Features After Antrectomy
Conditions: Helicobacter Pylori Infection;   Peptic Ulcer;   Bile Reflux;   Gastritis
Intervention:
20 Recruiting ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
Conditions: Dyspepsia;   Helicobacter Pylori Infection
Interventions: Drug: RHB-105;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years